People treated with immunotherapies are at high risk of fear of cancer recurrence or progression (FCR) due to the high levels of uncertainty regarding their treatment response, regular monitoring, and extended treatment duration. Fear-Less examined the levels of FCR in people with metastatic melanoma treated with novel therapies at Peter Mac and The Alfred. This presentation will explore the levels of FCR in this cohort and discuss implications for FCR interventions for people treated with immunotherapies. The Fear-Less stepped care intervention will be presented as an example of a novel feasible intervention to address this high unmet need.